[CAS NO. 94-09-7] Benzocaine
PRODUCTS SPECIFICATIONS [94-09-7]
DESCRIPTION [94-09-7]
Overview
| MDL | MFCD00007892 |
|---|---|
| Molecular Weight | 165.19 |
| Molecular Formula | C9H11NO2 |
| SMILES | O=C(OCC)C1=CC=C(N)C=C1 |
1 Publications Citing Use of MCE
Summary
Benzocaine shares a common receptor with all othe rLAs in the voltage-gated Na + channel , with an IC 50 of 0.8 mM tested with a potential of +30 mV.
IC50 & Target
IC50: 0.8 mM (Na + channel) [1] .
In Vitro
Benzocaine blocks μ1 wild-type Na + currents in a dose-dependent Manner. The Benzocaine concentration that inhibits 50% of Na + currents (IC 50 ) is estimated to be about 0.8 mM when a test potential of +30 mV is applied. The slope of the h∞ curve is also significantly reduced by benzocaine (from 6.6 to 9.9 mV). Mutation of μ1-N1584A also significantly increases the potency of Benzocaine. At 1 mM, Benzocaine blocks about 55% of wild-type Na + current but about 95% of μ1-N1584A mutant current. Benzocaine also appears to bind more strongly to its LA receptor in the N1584A mutant than in the wild type [1] . The inhibition of Ca 2+ uptake occurres at lower Benzocaine concentration (IC 50 =40.3±1.2mM) than that affecting the enzymatic activity [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Benzocaine is topically applied to the following species: dogs, domestic shorthair cats, Long-Evans rats, Sprague-Dawley rats, ferrets, rhesus monkeys, cynomolgus monkeys, owl monkeys, New Zealand White rabbits, miniature pigs, ICR mice, C3H mice, and C57BL/10SnJ mice. All animals, except mice and rats, receive a 2-second spray to the mucous membranes of the nasopharynx for an estimated dose of 56 mg. A 2-second spray to rodents' oral mucous membranes delivers too great a volume of fluid for these animals. The study is repeated in dogs several months later to confirm low response. Response to Benzocaine spray is observed in most animals tested, with response peaking between 15 and 30 minutes after dosing [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01951820 | University of Michigan|American Association of Endodontists |
Anesthesia of Mucous Membrane
|
August 2013 | Phase 4 |
| NCT01925469 | University of Pennsylvania |
Pain Relief|Analgesia
|
December 2011 | Phase 4 |
| NCT01274247 | Tel-Aviv Sourasky Medical Center |
Neonatal Tongue-tie|Maternal Nipple Pain Upon Breastfeeding|Neonatal Latch Difficulties
|
February 2011 | Phase 1|Phase 2 |
| NCT00846690 | The University of Texas Health Science Center, Houston |
Dental Pain|Postoperative Pain
|
January 2009 | Phase 4 |
| NCT01588535 | Arbor Pharmaceuticals, Inc. |
Pain|Otitis Media
|
May 2012 | Phase 2 |
| NCT02537314 | Vanderbilt University Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Obesity
|
September 2015 | Phase 1 |
| NCT01860235 | Franciscan University Center |
Local Anesthesia|Pain, Postoperative|Self-Perception
|
June 2010 | Not Applicable |
| NCT02674191 | Manal El Namrawy|Cairo University |
Orthodontic Anchorage Procedures
|
May 2016 | Not Applicable |
| NCT03790540 | Nourhan M.Aly|Alexandria University|University of Alexandria |
Anesthesia, Local
|
December 1, 2018 | Phase 2 |
| NCT02092454 | Otic Therapy, LLC |
Pain|Acute Otitis Media
|
September 2013 | Phase 2 |
| NCT05060913 | Dow University of Health Sciences |
Effect of Drug
|
November 17, 2021 | Early Phase 1 |
| NCT04317508 | Dina Youssef Attia|Alexandria University |
Anesthesia, Dental
|
November 1, 2019 | Phase 1|Phase 2 |
| NCT05564442 | Minia University |
Anesthesia, Local
|
June 5, 2022 | Not Applicable |
| NCT00716443 | Galderma R&D |
Nasolabial Folds
|
July 2008 | Phase 4 |
| NCT00148499 | Boehringer Ingelheim |
Pharyngitis
|
October 2005 | Phase 3 |
| NCT05507359 | Cairo University |
Pain
|
September 1, 2022 | Not Applicable |
| NCT02037893 | Currax Pharmaceuticals |
Acute Otitis Media
|
November 2013 | Phase 2 |
| NCT00474175 | Wyeth is now a wholly owned subsidiary of Pfizer|Church & Dwight Company, Inc.|Consumer Healthcare Products Association |
Toothache
|
May 2007 | Phase 4 |
| NCT02726620 | Vanderbilt University Medical Center|UMC Utrecht |
Hypotension
|
January 5, 2017 | Not Applicable |
| NCT01694004 | Vanderbilt University Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
The Effect of LCFA on Nutrient Absorption
|
November 2012 | Phase 1 |
| NCT03116737 | Lachlan Pharma Holdings |
Pain|Acute Otitis Media
|
January 3, 2017 | Phase 3 |
| NCT01429701 | EMS |
Eczema
|
May 2012 | Phase 3 |
| NCT03432923 | McNeil AB|Janssen Pharmaceutica N.V., Belgium|Johnson & Johnson Consumer and Personal Products Worldwide |
Sore Throat
|
February 2, 2018 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 605.36 mM )
H 2 O : 2 mg/mL ( 12.11 mM ; ultrasonic and warming and heat to 60°C)
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 6.0536 mL | 30.2682 mL | 60.5364 mL |
| 5 mM | 1.2107 mL | 6.0536 mL | 12.1073 mL |
| 10 mM | 0.6054 mL | 3.0268 mL | 6.0536 mL |
References
- [1] Wang GK et al. A common local anesthetic receptor for benzocaine and etidocaine in voltage-gated mu1 Na+ channels. Pflugers Arch. 1998 Jan;435(2):293-302.
- [2] Davis JA, et al. Benzocaine-induced methemoglobinemia attributed to topical application of the anesthetic in several laboratory animal species. Am J Vet Res. 1993 Aug;54(8):1322-6.
- [3] Di Croce D et al. Drug action of benzocaine on the sarcoplasmic reticulum Ca-ATPase from fast-twitch skeletal muscle. Naunyn Schmiedebergs Arch Pharmacol. 2015 Nov;388(11):1163-70.
Synonyms